Pfizer (NYSE:PFE) Trading 1.7% Higher – Time to Buy?

04 Jul 2026, 12:40 by Tristan Rich · The Markets Daily

Pfizer Inc. (NYSE:PFE – Get Free Report) traded up 1.7% on Thursday . The stock traded as high as $24.57 and last traded at $24.2910. 51,843,144 shares traded hands during trading, an increase of 21% from the average daily volume of 42,726,938 shares. The stock had previously closed at $23.88.

Analyst Ratings Changes

Several analysts have recently commented on the company. HSBC raised their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research note on Tuesday, June 9th. Finally, Wolfe Research restated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.82.

Get Our Latest Stock Analysis on PFE

Pfizer Price Performance

The stock has a market capitalization of $138.45 billion, a price-to-earnings ratio of 18.54 and a beta of 0.35. The business’s fifty day moving average price is $25.63 and its 200-day moving average price is $26.23. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the business posted $0.92 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s dividend payout ratio is 131.30%.

Institutional Investors Weigh In On Pfizer

A number of institutional investors and hedge funds have recently bought and sold shares of PFE. Horizon Financial Services LLC raised its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the 4th quarter worth about $26,000. YANKCOM Partnership bought a new stake in Pfizer in the 4th quarter worth about $28,000. HFM Investment Advisors LLC increased its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the last quarter. Finally, Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.